Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis

Xiaoping Qi,1 William W. Hauswirth,1,2 John Guy1,3

1Departments of Ophthalmology, Molecular Genetics and 2Microbiology, 3Neurology, University of Florida, College of Medicine, Gainesville, FL

Purpose: To ameliorate experimental optic neuritis by combining scavenging of superoxide by germ line increases in the extracellular superoxide dismutase (ECSOD) and hydrogen peroxide by viral-mediated gene transfer of the human catalase gene.

Methods: The human catalase gene inserted into recombinant adeno-associated virus (rAAV) was injected into the right eyes of transgenic mice overexpressing human ECSOD and wild-type littermates. Animals were simultaneously sensitized for experimental autoimmune encephalomyelitis (EAE) and then sacrificed one month later. The effects of antioxidant genes (ECSOD and catalase) on the histologic lesions of EAE were measured by computerized analysis of myelin area, optic disc area, extent of the cellular infiltrate, cerium derived H₂O₂ reaction product and extravasation of serum albumin detected by immunogold.

Results: Combined scavenging of H₂O₂ and superoxide with ECSOD and catalase suppressed demyelination by 72%, 54% due to catalase, and 19% due to ECSOD. Disruption of the blood-brain barrier was reduced 63% by the combined effects of catalase and ECSOD, 35% due to catalase and 29% due to ECSOD.

Conclusions: Transgene modulation of antioxidant enzyme defenses against both superoxide and its metabolite H₂O₂ provide a substantial suppressive effect against EAE in the optic nerve that may be a new therapeutic strategy for suppression of optic neuritis and multiple sclerosis.

Experimental autoimmune encephalomyelitis (EAE) is an autoimmune inflammatory disorder leading to primary central nervous system demyelination. EAE has been frequently used as an animal model for testing treatments against multiple sclerosis (MS) [1-16]. The optic nerve is a frequent site of involvement in both EAE and MS [17-23]. Reactive oxygen species (ROS) such as superoxide, hydrogen peroxide, nitric oxide and peroxynitrite are mediators of demyelination and disruption of the blood-brain barrier (BBB) in EAE [24-31]. The role ROS play in altering BBB permeability and demyelination has been inferred from the beneficial effect of monotherapy with free radical scavengers or antioxidants on EAE [27-31]. ROS scavengers include catalase and superoxide dismutase (SOD). SOD dismutes superoxide to hydrogen peroxide (H₂O₂) and catalase detoxifies the H₂O₂ to H₂O and O₂.

In a prior study, we targeted a single ROS, hydrogen peroxide, for detoxification by catalase gene inoculationn [23]. It reduced demyelination of the optic nerve by 38%. An approximately one-third suppressive effect on disease activity is achieved by currently available treatments for MS by utilizing a single drug [32]. Some studies have suggested that combination therapy may have a better suppressive effect on MS than monotherapy [33,34] although this is not always the case [35]. Here, we attempt to further ameliorate EAE by assessing the additional protective effects on experimental optic neuritis of combining in vivo scavenging of superoxide by germ line increases in the extracellular superoxide dismutase (ECSOD) and scavenging of hydrogen peroxide by viral mediated gene transfer of the human catalase gene.

METHODS

Recombinant adeno-associated virus: The adeno-associated virus (AAV) vector pTR-UF was used to accept the human catalase cDNA at the Not1 and Sal1 sites. The resulting pTR-CAT plasmid were amplified, then purified and packaged into serotype 2 rAAV. Briefly, recombinant AAV was purified through iodixanol step gradients and heparin-agarose affinity columns and assayed as previously described [36]. Each virus preparation contained 10¹¹ to 10¹² particles per milliliter and 10⁹ to 10¹⁰ infectious center units per milliliter.

Induction of EAE and intraocular injections: Two μl of recombinant adeno-associated virus (rAAV) catalase were injected into the vitreous cavity of 20 transgenic ECSOD mice, overexpressing human extracellular superoxide dismutase (ECSOD; a generous gift of Dr. James Crapo) and 20 wild-type littermates were also injected with AAV-catalase as controls. Briefly, ECSOD transgenic mice were constructed by injection of DNA containing the entire human ECSOD cDNA driven by a human β-actin promoter that was injected into pronuclei of fertilized eggs that were isolated from mice [(C57BL/6xC3H)F1x(C57BL/6xC3H)F1]. Surviving eggs were implanted into pseudopregnant foster mothers to gener-
ate offspring containing the ECSOD transgene. Mice expressing human ECSOD were identified using Southern blot analysis of DNA extracted from the tail and probed with the entire human ECSOD cDNA [37,38]. EAE was induced in the mice by sensitization with 0.2 cc of ultrasonically homogenized spinal cord emulsion in complete Freund’s adjuvant (Difco, Detroit, MI) that was injected subdermally into the nuchal area [30]. Mice were maintained in veterinarian-supervised animal care facilities that are fully accredited by the American Association of Laboratory Animal Science and they were humanely cared for in full compliance with ARVO guidelines.

**Immunoblotting and immunohistochemistry:** Retinal ganglion cells (RGC-5) were grown in Dulbecco’s Modified Eagle Medium (DMEM; Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin streptomycin. Medium (DMEM; Fisher Scientific) supplemented with 10% fetal calf serum. Cells were grown in 15 cm dishes that were infected with AAV containing the human catalase cDNA at multiplicities of infection (MOI) of 5,000 particles per cell. Cells were infected with AAV-GFP. Two days after AAV infections, cells were harvested. Briefly this involved washing the tryptasized cells in cold PBS, then manually homogenizing them. For immunodetection, 15 mg of homogenated protein was separated on a 10% SDS polyacrylamide gel and electro-transferred to a polyvinylidene fluoride membrane (BioRad, Hercules, CA). We immunostained the membrane with monoclonal anti-catalase antibodies raised against human ECSOD were identified using Southern blot analysis of DNA extracted from the tail and probed with the entire human ECSOD cDNA [37,38]. EAE was induced in the mice by sensitization with 0.2 cc of ultrasonically homogenized spinal cord emulsion in complete Freund’s adjuvant (Difco, Detroit, MI) that was injected subdermally into the nuchal area [30]. Mice were maintained in veterinarian-supervised animal care facilities that are fully accredited by the American Association of Laboratory Animal Science and they were humanely cared for in full compliance with ARVO guidelines.

**Immunoblotting and immunohistochemistry:** Retinal ganglion cells (RGC-5) were grown in Dulbecco’s Modified Eagle Medium (DMEM; Fisher Scientific) supplemented with 10% fetal bovine serum and 1% penicillin streptomycin (Sigma) at 37 °C with 5% CO₂. Cells were grown in 15 cm dishes that were infected with AAV containing the human catalase cDNA at multiplicities of infection (MOI) of 5,000 particles per cell. Cells were infected with AAV-GFP. Two days after AAV infections, cells were harvested. Briefly this involved washing the trypsinized cells in cold PBS, then manually homogenizing them. For immunodetection, 15 mg of homogenated protein was separated on a 10% SDS polyacrylamide gel and electro-transferred to a polyvinylidene fluoride membrane (BioRad, Hercules, CA). We immunostained the membrane with monoclonal anti-catalase antibodies (Sigma-Aldrich, St. Louis, MO, C0979, mol wt, 60 kDa) and then goat anti-mouse IgG horseradish peroxidase (HRP) conjugated secondary antibodies (Sigma-Aldrich). We detected specific binding of the secondary antibody, control specimens were incubated in the buffer, followed by the gold-labeled or Cy3 labeled antibody. Immunolabeled and control specimens were photographed by transmission electron microscopy without poststaining.

**Morphometric analysis:** Morphometric analysis was performed in masked fashion as previously described [23]. Briefly, images of toluidine blue stained sections of the optic nerve were captured with a video camera mounted on a light microscope and then the digital image was entered into computer memory. After initial calibration with a stage micrometer, the optic nerve head areas were manually traced using NIH IMAGE software and a MacIntosh Computer (Apple, Cupertino, CA). The number of glial cells and inflammatory cells in the retrobulbar optic nerve were also quantitated by thresholding of the darker staining cell nuclei. Using electron microscopy, identification of glial cells in the optic nerve was based on morphologic criteria. Fibrous astrocytes were identified by their round or elliptical nuclei with few clumps of chromatin in a relatively light karyoplasm that was surrounded by a voluminous pale cytoplasm with long processes and glial filaments. Inflammatory cells were identified by the prominent clumping of nuclear chromatin, ribosome rich cytoplasm that is clearly more electron dense than that of astrocytes and the presence of phagosomes with engulfed myelin debris.

Optic nerve specimens were examined without poststaining using a Hitachi H-7000 transmission electron microscope (Tokyo, Japan) operating at 75 kV. Photographs were made at a magnification of 2,500X. For quantitative analysis, micrographs of each optic nerve were digitized into computer memory by using a UMAX scanner (UMAX Data Systems, Fremont, CA). Extravasated serum albumin immunogold or H₂O₂ derived cerium perhydroxide were quantitated by thresholding the respective elements. Mean particle counts for each nerve were obtained by taking the mean value of the 10 micrographs. Each mean value was expressed as the number of elements per unit area. The extent of demyelination was quantitated by threshold measurements of the electron dense myelin sheaths that were derived from the axonal transmission electron micrographs for each optic nerve. Again using NIH IMAGE software, we utilized the threshold feature to outline the myelin sheaths for each micrograph. Glial or inflammatory cells that were also highlighted in the thresholded
Figure 1. Expression of extracellular superoxide dismutase and catalase. Immunofluorescence micrographs show expression of the human ECSOD (arrows) in the optic nerve of a representative transgenic ECSOD mouse (A), but it is absent in the optic nerve of a wild-type littermate (B). Transmission electron micrograph of the retrobulbar optic nerve of a transgenic ECSOD mouse reveals ECSOD immunogold (arrows) in the perivascular space and endothelia of the optic nerve (C), peripapillary choroid (E) and optic nerve sheath (F). Human ECSOD is absent in wild-type littermates (D). Immunoblotting shows increased catalase expression in cultured retinal ganglion cells infected with rAAV containing the gene for human catalase, relative to control RGC-5 cells infected with AAV-GFP (G). E represents endothelial cell. RBC represents red blood cell. L represents lumen. Cat represents catalase. GFP represents green fluorescent protein.
micrographs were removed manually by using the eraser function. To calculate the outlined myelin area we used the software “analyze” feature. Increases in myelin sheath area (less demyelination) thereby indicated a beneficial treatment effect. Grouped student t-tests were used to assess differences in the myelin areas, optic nerve head areas, optic nerve cell counts, hydrogen peroxide reaction product and extravasated albumin immunogold between the transgenic ECSOD mice and the wild-type littermates.

RESULTS

ECSOD and catalase expression: Expression of the human ECSOD was evident in the optic nerves of transgenic ECSOD mice (Figure 1A), but not in the wild-type littermates (Figure 1B). As implied by its name, ECSOD immunogold localized to the perivascular space and endothelial cells in the optic nerve (Figure 1C) and peripapillary choroid (Figure 1E). It was also represented in the meninges comprising the optic nerve sheath of ECSOD mice (Figure 1F). Human ECSOD immunogold was absent in the perivascular space of the littermates (Figure 1D). This distribution of ECSOD mirrored the presence of $\text{H}_2\text{O}_2$ in the EAE optic nerve. Immunobloting showed that retinal ganglion cells infected with rAAV containing the gene for human catalase had increased catalase expression relative to controls infected with AAV-GFP (Figure 1G).

Demyelination: Light microscopy of the EAE optic nerves revealed foci of demyelination, the hallmark of the histopathology of EAE and MS, was evidenced by loss of toluidine blue staining. This finding was seen to some degree in all animals sensitized for EAE. Transmission electron microscopy clearly demonstrated the benefits of anti-ROS gene therapy. Illustrative of the benefits of double protection, the right eyes of ECSOD mice that received the AAV-catalase gene inoculation had much less myelin fiber injury than the unprotected left eyes of wild-type mice. A representative micrograph of the right eyes of ECSOD mice further protected by catalase shows a near normal complement of optic nerve fibers with relatively preserved myelin lamellae (Figure 2A). These find-

![Suppression of demyelination](image)

Figure 2. Suppression of demyelination. Representative transmission electron micrographs of the retrobulbar optic nerve show many normal fibers and substantially less demyelinated and thinly myelinated axons following rAAV-catalase inoculation of the right eyes of transgenic ECSOD mice (A), relative to the unprotected left eyes of wild-type littermates in whom marked fiber loss, naked axons and those with thin sheaths of myelin were prominent ultrastructural findings (B). The barplot shows mean myelin areas of the retrobulbar optic nerve protected by both ECSOD and catalase (ECSOD OD), catalase (Wt OD), ECSOD (ECSOD OS) and unprotected EAE (Wt OS; C). Barplot (D) illustrates the preservation of myelin induced by ECSOD and catalase, catalase or ECSOD relative to unprotected nerves. Asterisk (*) represents $p<0.05$, double asterisks (**) represents $p<0.01$, Ax represents axon, As represents astrocyte process.
ings sharply contrasted with the unprotected left eyes of wild-type littermates where myelin and fiber loss was severe (Figure 2B). Here remaining axons were degenerating, enveloped by thin sheaths of myelin, or naked. Optic nerve fibers were replaced by a proliferation of astroglial processes.

Measurements of myelin area in wild-type mice not sensitized for EAE revealed a mean of 439,683 µm². This value was comparable to the normal unsensitized ECSOD transgenic mouse with a value of 424,878 µm². Relative to unsensitized wild-type mice, the myelin area of unprotected wild-type mice induced with EAE (Wt OS) was reduced by 55% (p<0.03). Quantitative analysis confirmed that in vivo scavenging of hydrogen peroxide by viral mediated catalase gene transfer and superoxide scavenging by ECSOD resulted in a mean myelin area of 340,236 µm² (ECSOD OD), thus reducing demyelination by 72% relative to a value of 197,517 µm² (Wt OS) for untreated wild-type mice with EAE (p<0.01; Figure 2C-D). This combined effect was greater than that of superoxide scavenging alone as ECSOD mice had 19% more myelin (less demyelination) with a mean myelin area of 235,123

![Image](http://www.molvis.org/molvis/v13/a1/)

Figure 3. Suppression of optic disc swelling. Representative light micrographs showing catalase and SOD suppressed optic nerve head edema (A) relative to the unprotected optic nerve (arrows) exhibiting marked swelling of the optic nerve head (B). The barplot of mean optic nerve head (ONH) areas shows that optic nerve head swelling (smaller ONH area) was reduced by combined ECSOD and catalase (ECSOD OD) treatment, catalase treatment (Wt OD), ECSOD treatment (ECSOD OS), but it was greatest with no treatment (Wt OS; C). Barplot (D) illustrates the reduction in ONH swelling induced by ECSOD and catalase, catalase or ECSOD relative to unprotected nerves. Asterisk (*) represents p<0.05, double asterisks (**) represents p<0.01.
µm² (ECSOD OS) than the mean of 197,517 µm² (Wt OS) for unprotected wild-type mice (p<0.05). It was also greater than the solo effect of catalase mediated scavenging of hydrogen peroxide with a mean myelin area of 304,190 µm² (Wt OD) versus 197,517 µm² (Wt OS) that reduced demyelination by 54% (p<0.01). Relative to unsensitized wild-type mice, myelin area was reduced by 23% even with combined scavenging (ECSOD OD). However, this difference was not statistically significant. Clearly, double protection against superoxide and H₂O₂ by ECSOD and catalase offered the best protection against the most desirable parameter sought after for treatment, amelioration of myelin fiber injury in the EAE optic nerve. The solo effect of catalase was better than that of ECSOD.

Optic disc edema: Optic disc edema, seen ophthalmoscopically in approximately one-third of patients with acute optic neuritis or multiple sclerosis, was evident in EAE animals in which lateral displacement of the peripapillary retina and filling of the optic cup indicated optic nerve head swelling at the light microscopic level. Relative to ECSOD and catalase-protected nerves (ECSOD OD; Figure 3A), optic nerve head swelling was most severe in the unprotected nerves of wild-type mice (Wt OS; Figure 3B). The combined effects of in vivo scavenging of hydrogen peroxide by viral mediated catalase gene transfer and superoxide scavenging by germ line increases of ECSOD reduced optic nerve head edema by 34% with a mean optic nerve head area of 29,821 µm² (ECSOD OD) relative to wild-type mice with a mean value of 45,354 µm² (Wt OS; p<0.01; Figure 3C-D). This combined effect was greater than that of superoxide scavenging alone. ECSOD mice had 16% less optic disc edema with a mean optic nerve head area of 38,092 µm² (ECSOD OS) relative to a mean of 45,354 µm² (Wt OS) for wild-type mice (p<0.05). Clearly, the additional benefit of ECSOD was not much greater than the solo effect of catalase that reduced optic disc edema by 32% with a mean optic nerve head area of 30,754 µm² (Wt OD) relative to 45,354 µm² for untreated eyes (Wt OS; p<0.01).

Optic nerve cell count: Mononuclear inflammatory cells and reactive astroglial cells predominantly involved the retrobulbar optic nerve of mice inoculated for EAE. ECSOD eyes inoculated with catalase had the greatest decrease in optic nerve cellularity. A representative light micrograph shows no inflammatory cells and a relatively normal complement of astroglial nuclei. (Figure 4A). In contrast, the unprotected nerves re-
revealed many mononuclear inflammatory cells in addition to the astroglia (Figure 4B). The combined effects of in vivo scavenging of hydrogen peroxide by viral mediated catalase gene transfer and superoxide scavenging suppressed the optic nerve cell count by 27% with mean of 243 cells per 10^5 µm^2 (ECSOD OD) relative to 335 cells per 10^5 µm^2 (Wt OS) for untreated wild-type mice (p<0.01) (Figure 4C-D). This combined effect was greater than that of superoxide scavenging alone as ECSOD mice (ECSOD OS) had 17% less inflammation with a mean cell count of 276 cells per 10^5 µm^2 versus a mean of 335 cells per 10^5 µm^2 for wild-type mice (Wt OS; p<0.05). It was slightly greater than the solo effect of catalase mediated scavenging of hydrogen peroxide with a mean cell count of 258 cells per 10^5 µm^2 (Wt OD) relative to 335 cells per 10^5 µm^2 (Wt OS) that reduced inflammation by 23% (p<0.01).

\( \text{H}_2\text{O}_2 \): Electron dense cerium derived \( \text{H}_2\text{O}_2 \) reaction product in the EAE optic nerve was greatest in the meninges of the optic nerve sheath, but was also evident in the optic nerve head and retrobulbar nerve, thus it was similar to the distribution of the ECSOD. Transmission electron micrographs show cerium perhydroxide reaction product in the lumen and perivascular space of ECSOD mice (Figure 5A) is increased relative to wild-type mice (Figure 5B). In the retrobulbar optic nerve of AAV-catalase gene inoculated eyes of ECSOD mice (ECSOD OD) a mean of 62 cerium perhydroxide particles per 2.6x10^6 µm^2 represented a 5% increase of \( \text{H}_2\text{O}_2 \) counts relative to 59 particles per 2.6x10^6 µm^2 for unprotected nerves of wild-type mice (Wt OD; Figure 5C-D). This slight difference was not statistically significant. Catalase gene inoculation into the eyes of wild-type mice (Wt OD) with a value of 38 particles per 2.6x10^6 µm^2 decreased \( \text{H}_2\text{O}_2 \) counts by 35% relative to the unprotected eyes of wild-type mice (Wt OS), but this difference was not statistically significant. However, cerium perhydroxide reaction product particles increased by 72% in the left eyes of ECSOD mice (ECSOD OS) with a mean of 106 particles per 2.6x10^6 µm^2 relative to unprotected left eyes of wild-type mice (Wt OS; p<0.01).

**Blood-brain barrier:** Disruption of the blood-brain barrier (BBB), a hallmark of optic neuritis and MS, was seen in all animals sensitized for EAE. A standard marker of BBB disruption is the extravasation of serum albumin that was detected by immunolabeling. Transmission electron microscopy of the optic nerves revealed albumin immunogold labeling in all animals with EAE. Extravasated albumin immunogold in the perivascular compartment located the foci of BBB disruption in EAE. Albumin immunogold confined to the intravas-
cular compartment indicated normal integrity of the BBB. Figure 6 shows representative transmission electron micrographs of the optic nerve of ECSOD mice inoculated with rAAV-catalase exhibiting less extravasated serum albumin (Figure 6A) than the control left eyes of wild-type littermates in which accumulation of extravasated albumin immunogold in the perivascular space is evident (Figure 6B). AAV-delivered catalase to the right eyes of transgenic ECSOD mice (ECSOD OD) reduced disruption of the BBB by 63%, with a mean value of 62 extravasated immunogold particles per 2.6x10^6 µm^2 relative to the left eyes of wild-type mice (Wt OS) with a mean value of 167 extravasated immunogold particles per 2.6x10^6 µm^2 (p<0.01; Figure 6C-D). This combined effect was greater than a value of 108 extravasated immunogold particles per 2.6x10^6 µm^2 for catalase gene transfer to the eyes of wild-type mice (Wt OD) that suppressed BBB disruption by 35% relative to unprotected left eyes (Wt OS; p<0.05). It was also greater than 119 extravasated immunogold particles per 2.6x10^6 µm^2 for the solo effect of germ line increases in ECSOD (ECSOD OS) that suppressed disruption of the BBB by 29% relative to untreated left eyes of wild-type littermates (Wt OS; p<0.05). Thus, combined scavenging of superoxide by ECSOD and hydrogen peroxide by catalase gene transfer restored integrity to the BBB.

**DISCUSSION**

Our results demonstrate that most parameters of experimental optic neuritis were substantially ameliorated by genetically induced expansion of two key antioxidant enzymes, catalase and ECSOD. Previously, we had demonstrated the beneficial effects of detoxification of a single ROS (H_2O_2) by catalase gene monotherapy. However, catalase only suppressed demyelination by 38% [23,30]. Since multiple ROS are likely involved in the pathogenesis of EAE and MS, it was reasonable to expect that detoxifying several detrimental ROS would have the best suppressive effect on disease activity. Here by combining ROS scavenging with ECSOD and catalase, we achieved a 72% reduction in the most important parameter of EAE studied, myelin injury to the optic nerve. This result was substantially better than the solo effect of catalase or ECSOD. Dai and coworkers attempted this approach in an animal model of antigen-induced arthritis in rodents [40]. In their study com-

---

**Figure 6. Restoration of blood-brain barrier integrity.** Transmission electron micrographs show that the combined effects of catalase and ECSOD markedly decreased extravasation of serum albumin labeled by immunogold (arrows) from the vessel lumen into the perivascular space (A), relative to perivascular accumulation of labeled serum albumin in the unprotected optic nerve (B). The barplot shows mean extravasated albumin immunogold counts in the retrobulbar optic nerves protected by ECSOD and catalase (ECSOD OD), catalase (Wt OD), ECSOD (ECSOD OS) or unprotected EAE (Wt OS; C). Barplot (D) illustrates the decrease in extravasated albumin immunogold in nerves treated with ECSOD and catalase, catalase or ECSOD relative to the unprotected nerves. Asterisk (*) represents p<0.05, double asterisks (**) represents p<0.01, L represents lumen.
bined scavenging with ECSOD and catalase did not have an additive protective effect on arthritis though each antioxidant gene had a protective effect as in our study, in which each also suppressed demyelination and disruption of the blood-brain barrier. Still, we found that the ECSOD did not exert a suppressive effect on optic nerve head swelling. Since optic nerve head edema is predominantly due to swelling of axons rather than accumulation of extracellular fluid, lack of intra-axonal ECSOD likely contributed to the relative lack of protection at the nerve head.

The linearity of the combined protective effect of ECSOD and catalase that suppressed blood-brain barrier disruption and demyelination in our study suggests that superoxide and hydrogen peroxide each has a direct detrimental effect on blood vessels and myelin in the EAE optic nerve. Still, superoxide and hydrogen peroxide can combine to generate a highly toxic metabolite, the hydroxyl radical. While scavenging of either reactant may then suppress hydroxyl radical formation, combined scavenging of either reactant may have no additional benefit. Clearly, this was not the case here. By detoxifying \( \text{H}_2\text{O}_2 \) to relatively nontoxic byproducts the slow effect of catalase was better than that of ECSOD that had the least protective effect. Several factors may have contributed to this result. Dismutation of superoxide by ECSOD increased extracellular \( \text{H}_2\text{O}_2 \) levels. Our prior publications have demonstrated the adverse impact of hydrogen peroxide on experimental optic neuritis [31,41]. Thus, accumulation of \( \text{H}_2\text{O}_2 \) in the extracellular compartment may have partially dampened the suppressive effect that dismutation of superoxide by ECSOD had on experimental optic neuritis. Still despite the increase in \( \text{H}_2\text{O}_2 \), ECSOD had a modest suppressive effect. In addition, the suppressive effect of ECSOD on experimental optic neuritis may have occurred perhaps by reducing generation of other pathogenic ROS. With less superoxide available to react with nitric oxide, levels of highly toxic peroxynitrite may have been suppressed and levels of nitric oxide increased [42]. Nitric oxide and peroxynitrite, formed by the reaction of nitric oxide and superoxide, also play a role in the pathogenesis of EAE and MS [43-45].

The antioxidant enzymes catalase and SOD can be used to target ROS for destruction, thus suppress tissue injury. However, there are limitations to the use of the proteins themselves as treatment agents in EAE and MS. First, the antioxidant enzyme (SOD) must be administered daily, even with conjugation of polyethylene glycol, to prolong the half-life of the enzyme [31,46]. Second, exogenous SOD or catalase are effective only during the periods of active BBB disruption when these high molecular weight proteins are able to penetrate the central nervous system (CNS) [47]. Finally, optic neuritis recurs in part due to the inability of the protein to cross the BBB after integrity is restored. Genetic augmentation of cellular defenses against superoxide and hydrogen peroxide helps surmount these limitations. Since transgene expression following delivery with the AAV vector is relatively long-lived, a single treatment may be sufficient. Still, treatment by intraocular injection incurs some risk, even with an AAV vector that is relatively nonpathogenic.

Our findings in acute EAE suggest that genetic amplification of cellular defenses against ROS may have a role in attenuating CNS injury associated with optic neuritis and perhaps MS. Determining whether comparable levels of protection are also maintained against the repeated demyelinating inflammation of chronic relapsing EAE may be key, if antioxidant gene transfers are to be applied in a clinical setting. While the 72% suppressive effect on demyelination achieved here is promising, our next steps are to tackle the pitfalls inherent in dual AAV infection of the retina and optic nerve and to demonstrate a protective effect by AAV mediated transfer of both genes (catalase and SOD), or perhaps even a chimeric SOD [48] on chronic EAE.

ACKNOWLEDGEMENTS

We wish to thank Mabel Wilson for editing of the manuscript. The work was supported by NIH EY 07982 (Dr. Guy), EY 11123, NS 36302 (Dr. Hauswirth) and Research to Prevent Blindness.

W.W.H. and the University of Florida could be entitled to patent royalties for inventions related to this work and W.W.H and the University of Florida both own equity in a company that may commercialize some of the technology described herein.

REFERENCES

1. Alvord EC Jr. The challenge: how good a model of MS is EAE today? Prog Clin Biol Res 1984; 146:3-5.
2. Baker D, Hankey DJ. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther 2003; 10:844-53.
3. Pedotti R, De Voss JJ, Steinman L, Galli SJ. Involvement of both allergic' and autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol 2003; 24:479-84.
4. Lisak RP, Zweibman B, Blanchard N, Rorke LB. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci 1983; 62:281-93.
5. Renno T, Taupin V, Bourbonniere L, Verge G, Tran E, De Simone R, Krakowski M, Rodriguez M, Peterson A, Owens T. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998; 12:376-89.
6. Bach JF. Cytokine-based immunomodulation of autoimmune diseases; an overview. Transplant Proc 1996; 28:3023-5.
7. Bettelli E, Nicholson LB. The role of cytokines in experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz) 2000; 48:389-98.
8. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000; 47:127-31.
9. Duong TT, Finkelman FD, Singh B, Strejan GH. Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J Neuroimmunol 1994; 53:101-7.
10. Floris S, Ruuls SR, Wierinckx A, van der Pol SM, Dopp E, van der Meide PH, Dijkstra CD, De Vries HE. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002; 127:69-79.
11. Martin R. Immunological aspects of experimental allergic en-
cephalomyelitis and multiple sclerosis and their application for new therapeutic strategies. J Neural Transm Suppl 1997; 49:53-67.

12. Ruuls SR, de Labie MC, Weber KS, Botman CA, Groenestein RJ, Dijkstra CD, Olsson T, van der Meide PH. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J Immunol 1996; 157:5721-31.

13. Schmidt J, Sturzebecher S, Toyka KV, Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001; 65:59-67.

14. van der Meide PH, de Labie MC, Ruuls SR, Groenestein RJ, Botman CA, Olsson T, Dijkstra CD. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiinflammatory activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 1998; 84:14-23.

15. Wender M, Michalak S, Wygladalska-Jernas H. The effect of short-term treatment with interferon beta 1a on acute experimental allergic encephalomyelitis. Folia Neupathol 2001; 39:91-3.

16. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64:91-100.

17. Hu P, Pollard J, Hunt N, Taylor J, Chan-Ling T. Microvascular and cellular responses in the optic nerve of rats with acute experimental allergic encephalomyelitis (EAE). Brain Pathol 1998; 8:475-86.

18. Guy J, Fitzsimmons J, Ellis EA, Beck B, Mancuso A. Intraorbital optic nerve and experimental optic neuritis. Correlation of fat suppression magnetic resonance imaging and electron microscopy. Ophthalmology 1992; 99:720-5.

19. Guy J, Mao J, Bigdoo GD Jr, Mancuso A, Quisling RG. Enhancement and demyelination of the intraorbital optic nerve. Fat suppression magnetic resonance imaging. Ophthalmology 1992; 99:713-9.

20. Guy J, Ellis EA, Rao NA. Hydrogen peroxide localization in experimental optic neuritis. Arch Ophthalmol 1990; 108:1614-21.

21. Guy J, Fitzsimmons J, Ellis EA, Mancuso A. Gadolinium-DTPA-enhanced magnetic resonance imaging in experimental optic neuritis. Ophthalmology 1990; 97:601-7.

22. Guy J, Mancuso A, Quisling RG, Beck R, Moster M. Gadolinium-DTPA-enhanced magnetic resonance imaging in optic neuropathies. Ophthalmology 1990; 97:592-9; discussion 599-600.

23. Guy J, Qi X, Hauswirth WW. Adenoviral gene therapy with catalase suppresses experimental optic neuritis. Arch Ophthalmol 1999; 117:1533-9.

24. Guy J, McGorray S, Fitzsimmons J, Beck B, Mancuso A, Rao NA, Hamed L. Reversals of blood-brain barrier disruption by catalase: a serial magnetic resonance imaging study of experimental optic neuritis. Invest Ophthalmol Vis Sci 1994; 35:3456-65.

25. International Working Group for Treatment Optimization in MS. Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neuro 2004; 11:43-7.

26. Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001; 7:49-58.

27. Cook SD, Devereux C, Troiano R, Bansil S, Zito G, Sheffet A, Jotkowitz A, Rohowsky-Kochan C, Dowling PC. Combination treatment of total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis. Acta Neurol Scand 1995; 91:22-7.

28. Visser LH, Beekman R, Tijssen CC, Utdehaag BM, Lee ML, Movig KL, Lenderink AW. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10:89-91.

29. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000; 316:743-61.

30. Oury TD, Piantadosi CA, Crapo JD. Cold-induced brain edema in mice. Involvement of extracellular superoxide dismutase and nitric oxide. J Biol Chem 1993; 268:15394-8.

31. Oury TD, Ho YS, Piantadosi CA, Crapo JD. Extracellular superoxide dismutase, nitric oxide, and central nervous system O2 toxicity. Proc Natl Acad Sci U S A 1992; 89:9715-9.

32. Oury TD, Chang LY, Marklund SL, Koprowski H, Hooper DC. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med 1997; 23:253-64.

33. Oury TD, Piantadosi CA, Crapo JD. Immunocystechemical localization of extracellular superoxide dismutase in human lung. Lab Invest 1994; 70:889-98.

34. Dai L, Claxson A, Marklund SL, Feakins R, Yousaf N, Chernajovsky Y, Winyard PG. Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes. Gene Ther 2003; 10:550-8.

35. Guy J, Ellis EA, Mames R, Rao NA. Role of hydrogen peroxide in experimental optic neuritis. A serial quantitative ultrastructural study. Ophthalmic Res 1993; 25:253-64.

36. Jung O, Marklund SL, Geiger H, Pedrazzini T, Busse R, Brandes RP. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res 2003; 93:622-9.

37. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266:4244-50.

38. Boullier AI, Rodriguez JJ, Touil T, Brochet B, Schmidt S, Abrous ND, Le Moal M, Pua JR, Jensen MA, Mayo W, Arnason BG,
Petry KG. Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci 2002; 22:123-32.

45. Cross AH, Manning PT, Stern MK, Misko TP. Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J Neuroimmunol 1997; 80:121-30.

46. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252:3582-6.

47. Guy J, Ellis EA, Hope GM, Rao NA. Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental optic neuritis. Arch Ophthalmol 1989; 107:1359-63.

48. Gao B, Flores SC, Leff JA, Bose SK, McCord JM. Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3. Am J Physiol Lung Cell Mol Physiol 2003; 284:L917-25.